EYLEA® (aflibercept) Injection
Regeneron has investigational product candidates progressing through all stages of human clinical trials.
Regeneron, in a global collaboration with Bayer HealthCare, is evaluating intravitreal aflibercept injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of eye diseases.
EYLEA® (aflibercept) Injection is a purified and formulated preparation of aflibercept, specifically for intravitreal injection. It is a fusion protein designed by Regeneron scientists to bind multiple isoforms of Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PlGF). VEGF-A and PlGF are proteins that are involved in the abnormal growth of new blood vessels in certain diseases. By blocking the effects of VEGF-A and PlGF, aflibercept injection may provide a therapeutic effect in patients suffering from various eye disorders characterized by abnormal blood vessels and leakage of fluid in the retina and macula.
Regeneron maintains exclusive rights to aflibercept injection in the U.S. Bayer HealthCare will market it outside the U.S., where the companies will share profits equally.
Development Phase: In two Phase 3 clinical studies (VIVID and VISTA) in patients with Diabetic Macular Edema and a Phase 3 study (VIBRANT) in patients with macular edema following Branch Retinal Vein Occlusion (BRVO).
This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.